Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418756
Status:
COMPLETED
Last Update Posted:
2010-03-19
First Post:
2007-01-03
Brief Title:
Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase I Open-label Two Period Single Center Study to Assess the Effect of 600 mg Daily Oral Dose of Rifampin CYP3A4 Inducer on the Pharmacokinetics of a Single 400 mg Oral Dose of Nilotinib in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effect of 600 mg daily oral dose of rifampin CYP3A4 inducer on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None